Glepaglutide acetate_product_DataBase

Bioactivity

Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].

Target

GLP-2R

In Vivo

Glepaglutide (ZP1848; 200 和 400 nmol/kg; 皮下注射; 每天两次; 持续 14 天) acetate 对小肠炎症大鼠显示出肠营养的作用[3]。 Animal Model:

Name

Glepaglutide acetate

Sequence

His-Gly-Glu-Gly-Thr-Phe-Ser-Ser-Glu-Leu-Ala-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Lys-Lys-Lys-Lys-Lys-Lys-NH2

Shortening

HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2

Formula

C199H329N53O57

Molar Mass

4376.13

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Reference

[1]. Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. [2]. Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37(1):18-36. [3]. Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. Gastroenterology, 2011, 140(5): S519.

PeptideDB

Glepaglutide acetate

CAS: F: C199H329N53O57 W: 4376.13